Charles Schwab
ACTU

Charles Schwab’s Actuate Therapeutics ACTU Stock Holding History

Charles Schwab’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,146
Closed -$30.5K – 3576
2026
Q1 		$30.5K Sell
11,146
-12,695
-53% -$52.6K ﹤0.01% 3444
2025
Q4 		$146K Buy
23,841
+9,076
+61% +$62.3K ﹤0.01% 3373
2025
Q3 		$98.8K Hold
14,765
– – ﹤0.01% 3394
2025
Q2 		$90.2K Buy
+14,765
New +$129K ﹤0.01% 3421

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Charles Schwab's ACTU Position: Q2 2026 in Review

Charles Schwab sold out of Actuate Therapeutics (ACTU) in Q2 2026, closing a stake of 11,146 shares — an estimated $30.5K sold.

Charles Schwab first reported a position in ACTU in Q2 2025 and held it in 4 quarters. The position peaked at $146K in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Charles Schwab reported no remaining Actuate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Charles Schwab sold 11,146 Actuate Therapeutics shares in Q2 2026, an estimated $30.5K.
  • Charles Schwab first reported a position in Actuate Therapeutics in Q2 2025 and held it in 4 quarters.
  • Charles Schwab's Actuate Therapeutics position peaked at $146K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.